ArticleInfectious diseases and therapy2026
Burden of Invasive Pneumococcal Disease and Community-Acquired Pneumonia in Adults: Significant Adverse Outcomes and Costs beyond Direct Treatment.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInfectious diseases, including invasive pneumococcal disease (IPD) and community‑acquired pneumonia (CAP), are associated with severe burden and adverse outcomes beyond the acute episode. The comprehensive burden has not been previously assessed in Finland. Here, we characterized adult patients (≥ 18 years) with IPD and CAP in Finland, followed them up for adverse outcomes, and estimated the economic burden.
methodsThis is a nationwide registry-based cohort study, including 2894 adults with laboratory-confirmed IPD; 129,203 adults with inpatient CAP; 126,314 adults with outpatient CAP; and their 760,748 age-sex-region-matched controls.
resultsOverall, 40-60% of the patients had at least one predefined medical risk factor; however, a substantial proportion (34-40%) of patients aged ≥ 65 years did not have any predefined risk factors. Patients aged ≥ 65 years with IPD and inpatient CAP had the highest rates of adverse outcomes, including recurrence, admission to institutional care, and acute myocardial infarction. IPD and CAP were associated with considerable attributable healthcare costs, including direct disease-specific costs, increased all-cause costs above them, and indirect costs due to work absenteeism. Serotypes included in the pneumococcal conjugate vaccines (PCVs) PCV13, PCV20, and PCV21 covered 43.0%, 61.1%, and 77.7% of IPD cases, respectively, in the age group ≥ 65 years in 2023-2024.
conclusionsIPD and CAP are associated with substantial morbidity, mortality, and economic burden, particularly among adults aged ≥ 65 years. In this age group, pneumococcal disease alone accounted for ~€39 million annually in total costs (inflated to 2023 values). As many older patients had no predefined medical risk factors, age‑based pneumococcal vaccination and broader use of higher‑valency conjugate vaccines seem warranted to reduce disease burden and societal costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.